Shopping Cart 0
Cart Subtotal
USD 0

Correvio Pharma Corp (COM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company's product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). Correvio has collaborations with other pharmaceutical companies to commercialize its products. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.

Correvio Pharma Corp (COM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Evotec and Artesian Therapeutics Enter into Agreement 13

Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16

Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17

Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18

Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20

Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21

Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22

Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23

Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24

Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25

Licensing Agreements 26

ZAO Firma Enters into Licensing Agreement with Correvio 26

Correvio International Enters into Licensing Agreement with ATCO Laboratories 27

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28

Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30

Eddingpharm Enters into Licensing Agreement with Correvio International 31

SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32

Equity Offering 33

Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33

Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34

Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35

Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37

Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39

Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41

Acquisition 43

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43

Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45

CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46

Correvio Pharma Corp-Key Competitors 47

Correvio Pharma Corp-Key Employees 48

Correvio Pharma Corp-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Financial Announcements 50

Aug 14, 2018: Correvio announces second quarter 2018 financial results 50

May 15, 2018: Correvio Announces First Quarter 2018 Financial Results 52

Mar 13, 2018: Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results 54

Nov 14, 2017: Cardiome Reports Third Quarter 2017 Financial Results 56

Aug 08, 2017: Cardiome Reports Second Quarter 2017 Financial Results 58

May 15, 2017: Cardiome Reports First Quarter 2017 Financial Results 60

Mar 07, 2017: Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results 61

Corporate Communications 63

May 16, 2017: Cardiome Reports Changes To Senior Management Team 63

Other Significant Developments 64

May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV 64

May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Correvio Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Evotec and Artesian Therapeutics Enter into Agreement 13

Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16

Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17

Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18

Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20

Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21

Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22

Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23

Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24

Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25

ZAO Firma Enters into Licensing Agreement with Correvio 26

Correvio International Enters into Licensing Agreement with ATCO Laboratories 27

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28

Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30

Eddingpharm Enters into Licensing Agreement with Correvio International 31

SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32

Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33

Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34

Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35

Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37

Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39

Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43

Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45

CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46

Correvio Pharma Corp, Key Competitors 47

Correvio Pharma Corp, Key Employees 48

Correvio Pharma Corp, Subsidiaries 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Correvio Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company's product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). Correvio has collaborations with other pharmaceutical companies to commercialize its products. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.

Correvio Pharma Corp (COM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Evotec and Artesian Therapeutics Enter into Agreement 13

Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16

Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17

Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18

Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20

Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21

Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22

Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23

Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24

Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25

Licensing Agreements 26

ZAO Firma Enters into Licensing Agreement with Correvio 26

Correvio International Enters into Licensing Agreement with ATCO Laboratories 27

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28

Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30

Eddingpharm Enters into Licensing Agreement with Correvio International 31

SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32

Equity Offering 33

Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33

Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34

Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35

Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37

Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39

Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41

Acquisition 43

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43

Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45

CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46

Correvio Pharma Corp-Key Competitors 47

Correvio Pharma Corp-Key Employees 48

Correvio Pharma Corp-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Financial Announcements 50

Aug 14, 2018: Correvio announces second quarter 2018 financial results 50

May 15, 2018: Correvio Announces First Quarter 2018 Financial Results 52

Mar 13, 2018: Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results 54

Nov 14, 2017: Cardiome Reports Third Quarter 2017 Financial Results 56

Aug 08, 2017: Cardiome Reports Second Quarter 2017 Financial Results 58

May 15, 2017: Cardiome Reports First Quarter 2017 Financial Results 60

Mar 07, 2017: Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results 61

Corporate Communications 63

May 16, 2017: Cardiome Reports Changes To Senior Management Team 63

Other Significant Developments 64

May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV 64

May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Correvio Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Evotec and Artesian Therapeutics Enter into Agreement 13

Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16

Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17

Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18

Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19

Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20

Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21

Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22

Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23

Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24

Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25

ZAO Firma Enters into Licensing Agreement with Correvio 26

Correvio International Enters into Licensing Agreement with ATCO Laboratories 27

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28

Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30

Eddingpharm Enters into Licensing Agreement with Correvio International 31

SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32

Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33

Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34

Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35

Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37

Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39

Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43

Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45

CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46

Correvio Pharma Corp, Key Competitors 47

Correvio Pharma Corp, Key Employees 48

Correvio Pharma Corp, Subsidiaries 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Correvio Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.